Form 4: Quantum-Si Inc. Executive Receives Restricted Stock Units

Grace Johnston, Chief Commercial Officer of Quantum-Si Inc., was granted 303,468 restricted stock units (RSUs) on March 15, 2024.

Summary

• On March 15, 2024, Grace Johnston, the Chief Commercial Officer of Quantum-Si Inc., received 303,468 restricted stock units (RSUs).
• Each RSU represents the right to receive one share of Quantum-Si Inc. common stock upon vesting.
• The RSUs vest in equal quarterly installments over four years, starting on June 20, 2024.
• Vesting is contingent upon Dr. Johnston's continued service with the company through each applicable vesting date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The RSU grant is a standard practice and indicates confidence in the executive's ability to contribute to the company's success. However, it doesn't provide any specific information about the company's financial performance or future outlook.

Positives

• The grant of RSUs to the Chief Commercial Officer aligns her interests with those of the shareholders, incentivizing her to contribute to the company's long-term success.
• The vesting schedule encourages continued service and commitment from the executive.

Risks

• The value of the RSUs is dependent on the future performance of Quantum-Si Inc.'s stock, which is subject to market risks and company-specific factors.
• If Dr. Johnston leaves the company before the RSUs fully vest, she will forfeit the unvested portion.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's financial performance or future prospects, focusing instead on the details of the RSU grant.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain key executives, aligning their interests with those of shareholders and incentivizing long-term value creation. This grant is typical for executives in similar roles at comparable companies.

Comparison to Industry Standards

• Equity grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Illumina, Pacific Biosciences, and Bio-Rad Laboratories also utilize RSUs and stock options to incentivize their leadership teams.
• The size of the grant is likely benchmarked against peer companies of similar market capitalization and stage of development.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns executive interests with long-term value creation.
• Employees may see the grant as a sign of the company's commitment to its leadership team.
• The grant has no immediate impact on customers, suppliers, or creditors.

Key Dates